[go: up one dir, main page]

EP3625338A4 - CONSTRUCTION OF A MINIMAL SACAS9-CRISPR / CAS SYSTEM FOR GENEDITATION AND TRANSCRIPTION REGULATION, OPTIMIZED BY EXTENDED GUIDE-RNA - Google Patents

CONSTRUCTION OF A MINIMAL SACAS9-CRISPR / CAS SYSTEM FOR GENEDITATION AND TRANSCRIPTION REGULATION, OPTIMIZED BY EXTENDED GUIDE-RNA Download PDF

Info

Publication number
EP3625338A4
EP3625338A4 EP17910146.4A EP17910146A EP3625338A4 EP 3625338 A4 EP3625338 A4 EP 3625338A4 EP 17910146 A EP17910146 A EP 17910146A EP 3625338 A4 EP3625338 A4 EP 3625338A4
Authority
EP
European Patent Office
Prior art keywords
geneditation
sacas9
crispr
rna
minimal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17910146.4A
Other languages
German (de)
French (fr)
Other versions
EP3625338A1 (en
Inventor
Zhen XIE
Dacheng Ma
Shuguang PENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Original Assignee
Tsinghua University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University filed Critical Tsinghua University
Publication of EP3625338A1 publication Critical patent/EP3625338A1/en
Publication of EP3625338A4 publication Critical patent/EP3625338A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP17910146.4A 2017-05-19 2017-05-19 CONSTRUCTION OF A MINIMAL SACAS9-CRISPR / CAS SYSTEM FOR GENEDITATION AND TRANSCRIPTION REGULATION, OPTIMIZED BY EXTENDED GUIDE-RNA Withdrawn EP3625338A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/085202 WO2018209712A1 (en) 2017-05-19 2017-05-19 Engineering of a minimal sacas9 crispr/cas system for gene editing and transcriptional regulation optimized by enhanced guide rna

Publications (2)

Publication Number Publication Date
EP3625338A1 EP3625338A1 (en) 2020-03-25
EP3625338A4 true EP3625338A4 (en) 2021-01-20

Family

ID=64273211

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17910146.4A Withdrawn EP3625338A4 (en) 2017-05-19 2017-05-19 CONSTRUCTION OF A MINIMAL SACAS9-CRISPR / CAS SYSTEM FOR GENEDITATION AND TRANSCRIPTION REGULATION, OPTIMIZED BY EXTENDED GUIDE-RNA

Country Status (3)

Country Link
EP (1) EP3625338A4 (en)
CN (1) CN110662835B (en)
WO (1) WO2018209712A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057961A1 (en) 2014-10-10 2016-04-14 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2016182959A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
WO2016201047A1 (en) 2015-06-09 2016-12-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
CA2999500A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
US12286727B2 (en) 2016-12-19 2025-04-29 Editas Medicine, Inc. Assessing nuclease cleavage
US12110545B2 (en) 2017-01-06 2024-10-08 Editas Medicine, Inc. Methods of assessing nuclease cleavage
EP3615672A1 (en) 2017-04-28 2020-03-04 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
EP3635104A1 (en) 2017-06-09 2020-04-15 Editas Medicine, Inc. Engineered cas9 nucleases
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
SG11202012228QA (en) 2018-06-08 2021-01-28 Modalis Therapeutics Corp MODIFIED Cas9 PROTEIN AND USE THEREOF
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
US12351838B2 (en) 2019-04-26 2025-07-08 Toolgen Incorporated Target-specific CRISPR mutant
WO2020227255A1 (en) * 2019-05-06 2020-11-12 The Regents Of The University Of Michigan Targeted therapy
WO2020236967A1 (en) * 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
CN110551760B (en) * 2019-08-08 2022-11-18 复旦大学 CRISPR/Sa-SeqCas9 gene editing system and its application
CN110423736B (en) * 2019-08-16 2021-09-17 中国人民解放军陆军军医大学第一附属医院 Base editing tool, application thereof and method for editing wide-window and non-sequence preference bases in eukaryotic cells
EP4127156B1 (en) 2020-03-31 2025-09-10 Metagenomi, Inc. Class ii, type ii crispr systems
CN112553246A (en) * 2020-12-08 2021-03-26 安徽省农业科学院水稻研究所 Efficient genome editing vector based on CRISPR-SaCas9 system and application thereof
WO2023028348A1 (en) 2021-08-27 2023-03-02 Metagenomi, Inc. Enzymes with ruvc domains
CN113717961B (en) * 2021-09-10 2023-05-05 成都赛恩吉诺生物科技有限公司 Fusion protein and polynucleotide, base editor and application thereof in preparation of medicines
AU2022396533A1 (en) 2021-11-24 2024-05-02 Metagenomi, Inc. Endonuclease systems
CN118742642A (en) * 2022-03-04 2024-10-01 益杰立科(上海)生物科技有限公司 Cas proteins and their uses and methods
WO2024138481A1 (en) * 2022-12-29 2024-07-04 中国科学院微生物研究所 Type i-f2 crispr-cas system for regulating and controlling eukaryotic cell gene transcription, and use thereof
CN116621947B (en) * 2023-07-18 2023-11-07 北京智源人工智能研究院 A kind of topological protein based on catenan skeleton, preparation method and application
CN119530192A (en) * 2023-09-08 2025-02-28 北京齐禾生科生物科技有限公司 A modular gene editing tool and its application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014150624A1 (en) * 2013-03-14 2014-09-25 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
WO2015089486A2 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
WO2015086795A1 (en) * 2013-12-13 2015-06-18 Cellectis Cas9 nuclease platform for microalgae genome engineering
WO2016201138A1 (en) * 2015-06-12 2016-12-15 The Regents Of The University Of California Reporter cas9 variants and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637739B2 (en) * 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2016205759A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
AU2016280893B2 (en) * 2015-06-18 2021-12-02 Massachusetts Institute Of Technology CRISPR enzyme mutations reducing off-target effects

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014150624A1 (en) * 2013-03-14 2014-09-25 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
WO2015089486A2 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
WO2015086795A1 (en) * 2013-12-13 2015-06-18 Cellectis Cas9 nuclease platform for microalgae genome engineering
WO2016201138A1 (en) * 2015-06-12 2016-12-15 The Regents Of The University Of California Reporter cas9 variants and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018209712A1 *
YAMADA MARI ET AL: "Crystal Structure of the Minimal Cas9 fromCampylobacter jejuniReveals the Molecular Diversity in the CRISPR-Cas9 Systems", MOLECULAR CELL, vol. 65, no. 6, 16 March 2017 (2017-03-16), pages 1109, XP029959270, ISSN: 1097-2765, DOI: 10.1016/J.MOLCEL.2017.02.007 *

Also Published As

Publication number Publication date
CN110662835B (en) 2023-04-28
CN110662835A (en) 2020-01-07
EP3625338A1 (en) 2020-03-25
WO2018209712A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
EP3625338A4 (en) CONSTRUCTION OF A MINIMAL SACAS9-CRISPR / CAS SYSTEM FOR GENEDITATION AND TRANSCRIPTION REGULATION, OPTIMIZED BY EXTENDED GUIDE-RNA
ZA201900986B (en) Plants and methods for increasing and decreasing synthesis of cannabinoids
LT3545079T (en) CONTROLLED TRANSCRIPTION
EP3610056A4 (en) SYSTEM AND PROCEDURE OF A COIL ACTUATOR
EP3448317A4 (en) REPAIR AND REPLACEMENT OF PERCUTANEOUS VALVE
EP3513579A4 (en) RECOGNITION OF AN EVENT LOCATION
EP3481479A4 (en) VENTILATION FOR A COMPONENT OF A BREATHER THERAPY SYSTEM
EP3734599C0 (en) VOICE DENOISE
HUE049181T2 (en) Design and signaling of a subband for a common control channel
EP3389490A4 (en) CALIBRATION OF IMU
EP3489555A4 (en) THROTTLE VALVE
EP3439544C0 (en) GAS SAMPLING CATHETER
DE112015006422T8 (en) Wastegate actuator and wastegate valve driver
IL265213A (en) System and method for damping a cover hole approved by a cover
EP3500209A4 (en) VALVE FOR FLUID OUTPUTERS
EP3497965A4 (en) ADJUSTMENT OF RAN ASSISTED FLOW RATE
EP3884939C0 (en) 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF
DK3191167T3 (en) Valve for supply of drug fluids
ZA201604177B (en) System and method for synthesis of speech from provided text
EP3692052A4 (en) SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF
PL3443987T3 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF DIET-INDUCED OBESITY
EP3594602A4 (en) VIBRATION-ABSORBING PIPING AND MANUFACTURING METHOD FOR IT
EP3589734A4 (en) REGULATION OF GENE EXPRESSION BY APTAMER-MODULATED RNASE-P SPLIT
IL284327A (en) Compounds and Methods for Inhibiting Expression of HMGB1
PL3729452T3 (en) System and method of training for the inhaler

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PENG, SHUGUANG

Inventor name: MA, DACHENG

Inventor name: XIE, ZHEN

RIN1 Information on inventor provided before grant (corrected)

Inventor name: XIE, ZHEN

Inventor name: PENG, SHUGUANG

Inventor name: MA, DACHENG

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201223

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/115 20100101ALI20201217BHEP

Ipc: C12N 9/22 20060101AFI20201217BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220413

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240409